Biopharmaceutical Leader Robert J. Spiegel, MD, FACP Appointed to the Athenex Board of Directors
“We are thrilled to add an industry executive with Dr. Spiegel’s deep drug development expertise to our Board of Directors,” said Dr.
“Athenex has an innovative Orascovery platform that can potentially transform chemotherapies and improve patients' lives. I am excited to join the Athenex Board of Directors and to help the Company further advance their broad clinical pipeline and bring important innovative products to cancer patients,” said
Founded in 2003,
Corporate Development and Investor Relations
Source: Athenex, Inc.